Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954664 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TRPA1TRPM8EPHX1LMNA | |
| SCHEMBL14037202 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TRPA1TRPM8EPHX1LMNA | |
| SCHEMBL14515031 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TRPA1TRPM8EPHX1LMNA | |
| SCHEMBL13927583 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TRPA1TRPM8EPHX1LMNA | |
| SCHEMBL14515030 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TRPA1TRPM8EPHX1LMNA | |
| SCHEMBL117885 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TRPA1TRPM8EPHX1LMNA | |
| SCHEMBL3338174 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TRPA1TRPM8EPHX1LMNA | |
| SCHEMBL115394 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TRPA1TRPM8EPHX1LMNA | |
| SCHEMBL21610687 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TRPA1TRPM8EPHX1LMNA | |
| SCHEMBL13206675 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TRPA1TRPM8EPHX1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3539942-A1 | METHOD FOR PRODUCING MENTHONES FROM ISOPULEGOL IN THE GAS PHASE | BASF SE (DE) | 2019-09-18 | — | — | EP | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120095249-A1 | METHODS OF MAKING EFAVIRENS AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-8080655-B2 | Methods of making efavirenz and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2011-12-20 | — | — | US | disclosed |
| US-20110015189-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2011-01-20 | — | — | US | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1377579-B1 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMA INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015189-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | CYP2F1, CYP4F11, CYP4F3 | ALDH1A1 290/4885TRPA1 4461/4885TRPM8 4583/4885 |
| US-20120095249-A1 | METHODS OF MAKING EFAVIRENS AND INTERMEDIATES THEREOF | CYP2F1, CYP4F11, CYP4F3 | ALDH1A1 223/4885TRPA1 4407/4885TRPM8 4519/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | ALDH1A1 2458/4885TRPA1 1926/4885TRPM8 2720/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | ALDH1A1 2458/4885TRPA1 1926/4885TRPM8 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.